Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis
Liviawati S. Wu(Janssen (United States)), Benjamin Wu(Amgen (United States)), Raju Subramanian(Gilead Sciences (United States)), Murad Melhem(Amgen (United States))
Cited by 6
Related Papers
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
|Drug Metabolism and Disposition|2002|346
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
|Drug Metabolism and Disposition|2002|325
Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
|Clinical Pharmacokinetics|2016|213
Comparison of Information-Dependent Acquisition, SWATH, and MS<sup>All</sup> Techniques in Metabolite Identification Study Employing Ultrahigh-Performance Liquid Chromatography–Quadrupole Time-of-Flight Mass Spectrometry
|Analytical Chemistry|2013|211
Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry
|Journal of Mass Spectrometry|2006|153